Saltar al contenido
República del Perú · Observatorio de la producción científica universitaria
OApol.org Observatorio de Inteligencia Científica Universitaria del Perú
OApol.org
Inicio Universidades Publicaciones Investigadores
Repositorios
Tesis y trabajos académicosRevistas
Indicadores
Ranking trimestralRanking por carreraObjetivos de Desarrollo SostenibleReporte OCDERed neuronal 3D
Acerca
MetodologíaPrivacidad

A SMARCA4-Deficient Uterine Sarcoma Arising in a Uterine Adenosarcoma: Expanding the Spectrum of SMARCA4-Deficient Uterine Neoplasms With Hybrid Morphologic Features

Rosas-Chavez F.; Baltodano B.; Fan F.; Chang S.; Sánchez-Sánchez A.A.; Arias-Stella J.A., III · International Journal of Surgical Pathology (2026) · DOI: 10.1177/10668969261483647

Resumen

Background: SMARCA4 genetic alterations have been associated with aggressive neoplasms in various organs. In the uterus, SMARCA4-deficiency has been reported rarely, typically presenting as undifferentiated uterine sarcoma with a poor prognosis and younger age onset. The spectrum of SMARCA4-driven uterine tumors has recently expanded reporting hybrid features to include adenosarcoma components. Clinical Presentation: We report a 27-year-old woman who presented with abnormal uterine bleeding. The endometrial curettage revealed a high-grade adenosarcoma. One month later, the patient underwent tumor debulking surgery. The histologic examination showed a tumor with leaf-like architecture and marked stromal atypia. The stromal component exhibited epithelioid and rhabdoid features, with cells arranged in nests. Extensive lymphovascular invasion and infiltration of surrounding tissues were noted. SMARCA4 mutation was confirmed by next-generation sequencing, with no other mutations detected. Despite prompt initiation of aggressive chemotherapy, the cancer continued to spread to the lungs and peritoneum. The patient died 19 months after the initial presentation. Conclusion: This case report reinforces the emerging pattern of SMARCA4-deficient tumors presenting aggressively in premenopausal women with hybrid morphologic features. It highlights the importance of molecular testing in patients of all ages and the need for early recognition and prompt treatment of tumors harboring mutations associated with rapid progression. © The Author(s) 2026

Instituciones: Universidad Peruana de Ciencias Aplicadas